Literature DB >> 20465501

Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Arun Balakumaran1, Pamela Gehron Robey, Neal Fedarko, Ola Landgren.   

Abstract

Multiple myeloma (MM) is the second most common hematological malignancy, with an overall survival of 4-6 years. It is always preceded by a premalignant stage called monoclonal gammopathy of unknown significance (MGUS). Importantly, at this time we lack reliable predictors to determine who will progress from MGUS to MM, and who will remain stable. The bone marrow microenvironment plays a key role in myelomagenesis (growth, survival and migration of malignant plasma cells). In the present review, we summarize and discuss our current understanding of the bone marrow microenvironment and its compartments in relation to myelomagenesis. Although it remains to be proven, we believe that an improved characterization of the cellular constituents, the extracellular matrix components and the soluble factors of the bone marrow could open up novel avenues to better understand underlying mechanisms of the transformation from MGUS to MM. Ultimately, this will lead to the development of early treatment of high-risk precursor disease aimed to delay/prevent MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465501      PMCID: PMC2945699          DOI: 10.1586/erm.10.31

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  133 in total

Review 1.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

2.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

Review 3.  Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.

Authors:  Mark Bloomston; Emmanuel E Zervos; Alexander S Rosemurgy
Journal:  Ann Surg Oncol       Date:  2002-08       Impact factor: 5.344

4.  Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways.

Authors:  Joy Y Wu; Louise E Purton; Stephen J Rodda; Min Chen; Lee S Weinstein; Andrew P McMahon; David T Scadden; Henry M Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

5.  Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.

Authors:  Kavita M Dhodapkar; Scott Barbuto; Phillip Matthews; Anjli Kukreja; Amitabha Mazumder; David Vesole; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

6.  Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity.

Authors:  A J Docherty; A Lyons; B J Smith; E M Wright; P E Stephens; T J Harris; G Murphy; J J Reynolds
Journal:  Nature       Date:  1985 Nov 7-13       Impact factor: 49.962

7.  Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.

Authors:  Barbara Zdzisińska; Adam Walter-Croneck; Martyna Kandefer-Szerszeń
Journal:  Leuk Res       Date:  2008-05-09       Impact factor: 3.156

8.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.

Authors:  Z Werb; C L Mainardi; C A Vater; E D Harris
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

9.  Non-Hodgkin lymphoma of bone.

Authors:  E M Braunstein; S J White
Journal:  Radiology       Date:  1980-04       Impact factor: 11.105

10.  Stromal gene signatures in large-B-cell lymphomas.

Authors:  G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

View more
  19 in total

Review 1.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 2.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

Review 3.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

4.  Multiple myeloma precursor disease.

Authors:  Ola Landgren; Adam Justin Waxman
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

Review 5.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

6.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

7.  A role for activator of G-protein signaling 3 (AGS3) in multiple myeloma.

Authors:  Shan Shao; Xianting Huang; Yuchan Wang; Song He; Xiaohong Xu; Xinghua Zhu; Xiaojing Yang; Zongmei Ding; Li Yao; Yuejiao Huang; Chun Wang
Journal:  Int J Hematol       Date:  2013-12-05       Impact factor: 2.490

Review 8.  The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.

Authors:  T Dosani; M Carlsten; I Maric; O Landgren
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

9.  The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma.

Authors:  Anne M Sponaas; Siv H Moen; Nina B Liabakk; Emadoldin Feyzi; Toril Holien; Solveig Kvam; Lill Anny G Grøseth; Berit Størdal; Glenn Buene; Terje Espevik; Anders Waage; Therese Standal; Anders Sundan
Journal:  Immun Inflamm Dis       Date:  2015-03-02

Review 10.  Immunological dysregulation in multiple myeloma microenvironment.

Authors:  Alessandra Romano; Concetta Conticello; Maide Cavalli; Calogero Vetro; Alessia La Fauci; Nunziatina Laura Parrinello; Francesco Di Raimondo
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.